electra therapeutics announces first patient dosed in phase 1 study of ipsoprubart ela026 in t cell malignancies

MEDIA_SOCIALSCIENCECRISISLEX_C03_WELLBEING_HEALTHTAX_MILITARY_TITLE_OFFICER

The full article is on the original publisher site. This page only shows the headline and a very short excerpt.